Retacrit(epoetin alfa-epbx)使用说明 Retacrit | epoetin alfa-epbx 2018年5月15日,美国食品和药物管理局批准Retacrit作为Epogen/Prorit的生物仿制药,用于治疗透析患者和非透析患者因慢性肾病(CKD)导致的贫血,艾滋病毒感染患者使用齐多夫定以及伴随骨髓抑制化疗的效果。...
See risks & benefits. Find RETACRIT (epoetin alfa-epbx), the first FDA-approvedESA biosimilar to Epogen (epoetin alfa) & Procrit (epoetin alfa) in the US.
Retacrit (epoetin alfa-epbx) Injection is an erythropoiesis-stimulating agent (ESA) indicated for treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis; zidovudine in patients with HIV-infection; the effects of concomitant myelosuppressive chemotherapy, ...
美国FDA于2018年5月15日批准Hospira公司(Hospira Inc.,辉瑞Pfizer旗下子公司)的Retacrit(epoetin alfa-epbx)作为生物仿制药(biosimilar)用于治疗因多种原因引起的贫血,包括慢性肾病,癌症化疗,HIV感染者服用齐多夫定治疗等;也可用于外科手术前后以减少患者因手术过程中失血而导致的输血.夏训明...
We compare the safety of epoetin alfa-epbx versus epoetin alfa based on a pooled analysis of findings from 2 randomized, double-blind, comparative clinical studies, and report new data for the long-term safety of epoetin alfa-epbx.doi:10.1016/j.xkme.2019.06.009Jay B. Wish...
Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbxdoi:10.1016/j.xjtc.2020.07.018Alejandro Murillo-Berlioz MD aNicole R. Guinn MD bJerrold H. Levy MD a bCarmelo A. Milano MD aJTCVS Techniques...